MedTrace Logo

The Response to Atropine Drops (RAD) Study

NCT05199597 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-07

No results posted yet for this study

Summary

The purpose of this study is to examine the comfort of giving low concentration atropine eye drops.

Conditions

  • Myopia

Interventions

DRUG

0.01% atropine

0.01%, room temp, Lab A

DRUG

0.05% atropine

0.05%, room temp, Lab A

DRUG

0.05% atropine

0.05%, refrigerated, Lab A

DRUG

0.05% atropine

0.05%, room temperature, Lab B

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2022-06-15
Completion
2022-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05199597 on ClinicalTrials.gov